The Janus kinase (JAK) signaling pathway plays a crucial role in psoriasis pathogenesis, mediating the effects of various proinflammatory cytokines. JAK inhibitors have emerged as a targeted therapeutic strategy, offering potential benefits in controlling this complex condition. At Ace Therapeutics, we specialize in providing comprehensive preclinical research services to support the development of these innovative therapies for psoriasis.

Role of JAK Inhibitors in Therapy of Psoriasis

JAK inhibitors function by blocking the JAK-STAT signaling pathway, which is critical for the transduction of signals from various inflammatory cytokines. By inhibiting JAKs, these drugs prevent the activation of STAT proteins, leading to a decrease in the production of pro-inflammatory cytokines that are pivotal in the pathogenesis of psoriasis. This mechanism of action positions JAK inhibitors as a promising therapeutic option for patients with moderate-to-severe psoriasis. Clinical trials have demonstrated the efficacy of JAK inhibitors like tofacitinib, which has shown significant PASI (Psoriasis Area and Severity Index) response rates in various studies.

Fig. 1 Mechanisms of action of Janus kinases. (Słuczanowska-Głąbowska S, et al., 2021)

What Can We Do for the Development of JAK Inhibitors?

Our expertise in preclinical research facilitates the thorough evaluation of these compounds, ensuring they meet the rigorous standards needed for clinical application. We employ cutting-edge methodologies to assess the pharmacodynamics and pharmacokinetics of JAK inhibitors, contributing valuable insights into their safety and efficacy profiles.

In Vitro Assays and Cellular Models

Ace Therapeutics specializes in conducting in vitro assays to evaluate the potency and selectivity of JAK inhibitors.

• Cytokine-Induced Signaling Assays: We assess the ability of JAK inhibitors to block cytokine-induced JAK/STAT signaling in various immune cells, providing insights into their potential therapeutic efficacy.
• Inflammatory Protein Production Analysis: By quantifying the production of key inflammatory proteins, we help determine the inhibitory effects of JAK inhibitors on cytokine-driven inflammation.

In Vivo Pharmacological Studies

Our in vivo services are designed to evaluate the efficacy and safety of JAK inhibitors in relevant animal models.

• Disease Model Development: We develop and utilize animal models that recapitulate the key features of psoriasis to test the therapeutic potential of JAK inhibitors.
• Pharmacodynamic and Pharmacokinetic Assessments: Through these assessments, we provide comprehensive data on the absorption, distribution, metabolism, and excretion of JAK inhibitors, ensuring that our clients have a clear understanding of their compounds' behavior in vivo.

Safety Assessment

Safety is a paramount concern in drug development. Our services include comprehensive toxicity assessments to evaluate the safety profile of JAK inhibitors. We perform a range of studies, including dose-ranging studies and evaluation of off-target effects, to provide a thorough safety assessment that supports further development.

The development of JAK inhibitors for psoriasis presents a significant opportunity for therapeutic advancement. Ace Therapeutics is committed to providing comprehensive preclinical services to support the development of these innovative treatments, leveraging our expertise and resources to help our clients achieve their research objectives. Contact us today to learn more about how we can assist you in your drug development journey.